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ABSTRACT
Background. Cysteamine has improved survival and progno-
sis in cystinosis. Increasing numbers of patients reach adult-
hood and face new challenges such as compliance that wanes
over time. The aim of this study was to evaluate adherence to
cysteamine treatment in a group of cystinotic patients in Spain
in an attempt to identify potential therapy pitfalls and improve
the overall care of affected individuals. Despite the impact of
cysteamine on prognosis, there is a paucity of data regarding
adherence.
Method. Thirty-four cystinotic patients (21 male) 38% ≥18
years were enrolled in a voluntary, anonymous survey. Replies
were obtained from patients (15/34), mothers (11/34), fathers
(4/34) and both parents (4/34).
Results. Patient age (median and interquartile range) at diag-
nosis was 1 year (0.57–1), and patient age at Cystagon® initi-
ation was also 1 year (0.8–1.8). Sixteen (47%) were kidney
transplant (KTx) recipients; six were retransplanted. Age at
first KTx 10 years (8.7–13.7). Patient understanding of multior-
gan involvement in cystinosis: 4.1 organs reported; eye 97%
and kidney 91%. Cysteamine was given by mother (100%) and
father (83%) in <11 year olds, or self-administered (94%) in
≥11 year olds. Four daily doses in 89% versus 56% in <11 year
olds or ≥11 year olds, with fixed schedule in 94% versus 50% in
<11 or ≥11 year olds and progressive loss of reminders over
time. Furthermore, 44% complained of unpleasant smell. Mo-
tivation for treatment compliance was 100% versus 40% in <11
versus ≥11 year olds, respectively. Disease impact in patients
<18 years is as follows: school (29%), social (14%), ‘feeling dif-
ferent’ (10%); in patients ≥18 years: ‘feeling different’ (62%),
professional (39%) and job absenteeism (31%). Referring phys-
ician: paediatric nephrologist (94%) and nephrologist (63%) in
<11 versus ≥11 year olds. Ophthalmological follow-up: 83%
versus 38% in <11 versus ≥11 year olds. Patient opinion of
physician expertise: paediatric nephrologist (94%) and neph-
rologist (44%). New treatment options (65%) and better infor-
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Conclusion. Treatment with Cystagon is effective in young pa-
tients. However, adherence diminishes over time in adolescents
and adults despite disease impact. Strategies such as better
information on the disease, patient self-care promotion and fa-
cilitated transition to adult healthcare services are required to
improve compliance and the clinical management of cystinosis.
Keywords: adherence, cysteamine, cystinosis, prognosis,
transition
INTRODUCTION
Cystinosis is a rare autosomal recessive disorder of the lyso-
somal cystine transporter cystinosin [1] encoded by the CTNS
gene (17p13) [2], which affects ∼1–2 per 100 000 newborns
[3]. Most patients exhibit the severe infantile form, leading to
end-stage kidney disease (ESKD) by the end of the first decade
in the absence of specific cystine-depleting treatment [1] and
premature death before the second decade [4–7], whereas up
to 5% present the milder late-onset form of the disease [8].
Treatment with Cysteamine (Cystagon®), the only available
cystine-depleting drug from lysosomes in Spain, and renal
transplantation have improved the prognosis of cystinosis [1];
consequently, increasing numbers of affected patients are
reaching adulthood [9, 10]. Early and sustained treatment with
cysteamine has improved renal outcome in cystinosis [11] by
delaying progression to ESKD [4]. Furthermore, correct cy-
steamine administration also delays the onset and reduces the
severity of extra-renal complications [5], leading to extended
life expectancy and longer patient survival [6].
This changing scenario in cystinosis poses new challenges
such as long-term compliance with a lifelong treatment [7], a dif-
ficult task in patients who take multiple medications and supple-
ments [12], are exposed to potential cysteamine-related side
effects (gastric intolerance, unpleasant smell and halitosis, among
others) [13] and need to follow an ‘every 6 hour’ (Q6h) [14] dose
schedule of immediately released cysteamine (Cystagon®) [15].
Last but not least, cystinosis is a good model of a rare ‘paediatric
disease’ extending to adult practice [4, 6, 16]; however, few re-
sources are in place to prevent inadequate transition to adult
services [17], management of systemic disease involvement is
poor, reference centres are lacking in many countries and, com-
monly, awareness among adult physicians is low [18]. Cystinotic
patients are often transferred in a suboptimal process to adult
services where they feel depressed and ‘lost in the system’ [19].
New therapeutic approaches are based on a patient-centred
strategy of disease education, adherence, support by patient ad-
vocacy groups and a new culture of patient ‘self-care’ [20].
MATERIALS AND METHODS
Fifty-six individuals with cystinosis under the regular care of
29 different paediatric or adult nephrologists in 22 different
hospitals received chronic treatment with cysteamine (Cysta-
gon®) in Spain in 2012. All physicians caring for a patient
with cystinosis were personally invited to participate in this
study so that patients and families could be informed, give
their consent and be provided with a printed copy of the
questionnaire.
An anonymous written survey was distributed among pa-
tients diagnosed with cystinosis at the time of a regular renal
care follow-up visit at different hospitals in Spain in 2012. Pa-
tients and/or their parents, if applicable, were invited to volun-
tarily participate by completing a questionnaire, the estimated
duration of which was ∼10 min. In order to guarantee patient
confidentiality and voluntary enrolment, a ‘take home’ option
was offered and patients could later submit the document to a
central site, thereby preserving individual information blinded
to their physicians. Patients’ geographic location or centre
identification data were not provided. The survey consisted of
21 multiple-choice questions covering four main areas: (i)
knowledge of cystinosis and impact of the disease; (ii) adher-
ence to cysteamine treatment; (iii) monitoring of cysteamine
therapy and (iv) measures to improve compliance. The survey
was promoted by Orphan Europe (a pharmaceutical company
specialized in orphan diseases and a member of the Recordati
Group), which created, designed and distributed it via
company representatives to physicians caring for known cysti-
notic patients treated with cysteamine (Cystagon®). Another
firm, A.C. Nielsen Company, made the overall analysis of the
results in an independent manner. The results were expressed
as median and inter-quartiles and patients were divided into
two groups: those under and over 11 years of age.
RESULTS
Demographics
Thirty-four paediatric and adult patients (21 male and 13
female) with nephropathic cystinosis participated in the study,
a figure representing 61% of the known treated cystinotic
population in Spain. The questionnaire was completed by pa-
tients (15/34), their mother (11/34), father (4/34) or both
parents (4/34). Age distribution was as follows: 12 patients
(35%) 0–6 years, 6 (18%) 7–11 years, 3 (9%) 12–17 years and
13 (38%) ≥18 years old. All responders suffered from the in-
fantile form of the disease. Out of 34 (47%), 16 had received at
least one kidney transplant (KTx) and 6 (18%) had more than
one. Remarkably, adult patients constituted almost 40% of the
study cohort; indeed, 12 of 13 patients over 18 years of age
were KTx recipients and half (6/12) had received more than
one graft. At the time of the study, 22 patients were being fol-
lowed up in paediatric nephrology services, whereas 12 were
receiving care in adult nephrology departments. The main
clinical characteristics of patients are described in Table 1.
This cohort belongs to the population of cystinotic patients
in Spain that currently consists of 29% children, 16% teenagers
and 55% adults. However, a lower percentage of cystinotic
adults was enrolled in the study because ∼32% of patients over
the age of 18 did not participate.
Age at diagnosis and initiation of cysteamine
Cystinosis was diagnosed during infancy in 27 patients
(79%); of them, 15 (44%) were diagnosed within the first year
























cysteamine was initiated before the second year in 89% and
within the first year in 56%. A significant difference was ob-
served in age at cysteamine initiation between patients under
or over 11 years of age at the time of the study, with earlier ad-
ministration in patients diagnosed more recently (median 1
versus 2.7 years old, P < 0.001) (Table 1).
Knowledge on cystinosis and impact of the disease
Patients were aware of the systemic nature of cystinosis and
reported the almost universal involvement of organs that
occurs in cystinosis such as eyes (97% responders) and kidneys
(91% responders), but also others such as muscles (44%), pan-
creas (35%), gastrointestinal (32%), central nervous system
(CNS) (32%), neurological (24%), cardiovascular (21%) and
testicular (15%), with a mean of 4.1 affected organs reported
per patient.
The impact of the disease on quality of life (QOL) was re-
ported to be greater in adults than in children. Thus, 62% of
affected adults complained of feeling different, 39% expressed
professional limitations, 31% required job absences and 8% re-
ferred to compromised social life and rejection, whereas in pa-
tients under 18 years old, cystinosis negatively influenced
school attendance (29%), learning ability (5%) and social life
(14%), but only 10% reported feeling different.
Adherence to cysteamine
In children under the age of 11, cysteamine was mainly ad-
ministered by the mother (100%) and father (83%), but also
by other relatives (28%) or by a teacher or school nurse (33%).
In contrast, patients over 11 were largely responsible for their
own treatment (94%), with less involvement of relatives
(mother 25% and father 6%) or others.
With respect to treatment adherence, 89% of patients under
11 received cysteamine (Cystagon®) following a fixed four-
daily dose schedule compared with only 56% of older patients
who took the correct number of four doses per day (Figure 1).
Furthermore, up to 41% of patients or their relatives had asked
their doctor for a reduction in the number of daily doses: 27%
stated their doctors had refused to reduce the number of
doses, but 15% reported their physicians had agreed.
Nevertheless, whereas the majority of children under 11 fol-
lowed the cysteamine prescription correctly (94%), the per-
centage dropped dramatically in older patients (50%) who
reported frequent schedule changes (13%), missed doses
(13%), never using the recommended doses (18%) or even not
caring about drug prescription (6%) (Figure 2). Although up
to 65% of patients took advantage of alarms or dose-reminder
tools, the study demonstrated progressive waning in their use
over time, as only 46% of adult patients used dose reminders.
Regarding patient motivation for treatment, 72% of patients
under 11 were always motivated, and 39% expressed more mo-
tivation before a clinical appointment. In contrast, fewer older
patients expressed feeling always motivated (38%) and, re-
markably, 38% expressed no motivation at all, with low in-
creased interest before/after a clinical appointment or before a
blood test (Figure 3). Patients complained of unpleasant smell
(44%), too many medications (44%), excessive number of
daily doses (35%) and gastrointestinal side effects (24%),
among others. New therapeutic strategies focussed on lower-
frequency doses, fewer pills and/or reduced pill size (60%) as
well as additional education on the disease (42%) were de-
manded to improve adherence to cystinosis therapy.
Adherence to medical control
For patients under the age of 11 years, paediatric nephrolo-
gists represented the referring physicians and 94% were con-
sidered disease experts. Remarkably, adult nephrologists were
considered disease experts by only 44% of patients. Further-
more, patients stated that only 56% or 44% of paediatric or
Table 1. Clinical characteristics of cystinotic patients at baseline (n = 34)
n Years (md; interquartile)
Age at the time of the study (years)
<11 18 (53%)
≥11 16 (47%)






Age at cysteamine initiation 1 (0.8–1.85)




















Former education 5 (15%)
NR 8 (24%)
NR, no reply.
F IGURE 1 : Number of self-reported daily cysteamine (Cystagon®)
























adult nephrologists, respectively, provided them with sufficient
information regarding cystinosis. Patients were under paediat-
ric nephrologist care up to the age of 18, after which they were
progressively transferred to adult nephrologists (13 of 34 pa-
tients). Several other medical specialists were also involved in
the care of cystinotic patients: ophthalmologists (62%), endo-
crinologists (47%), transplant physicians (27%), neurologists
(15%), dermatologists (6%) and others (18%). However,
whereas 83% of younger cystinotic patients received regular
ophthalmology care, the percentage dropped to 38% in those
over 11 years of age.
DISCUSSION
We were able to collect self-reported data from 61% of the cy-
stinotic patients receiving cysteamine in Spain. This study pro-
vides an insight into the current scenario of the disease in
Spain, with a significant proportion (38%) of patients over 18
years of age, mostly kidney-transplanted recipients, being
under the care of adult physicians. The main findings included
good compliance in children under the age of 11 and a decline
in cysteamine adherence after puberty associated with less par-
ental supervision, decreasing use of dose reminders, very low
motivation rates of treatment compliance in older patients,
substantial impact on QOL and inadequate transition to adult
medical care [19], with many centres caring for one individual
patient. Specifically, our cohort of 34 individuals was under
the care of 22 different doctors working at 20 different
hospitals, very telling of the dispersion of patients and conse-
quent lack of physician/health system awareness of, and ex-
pertise in, cystinosis, which may also, at least in part, explain
why a significant percentage of affected adults did not partici-
pate in the survey.
Most patients exhibit the severe infantile form of the
disease and are at risk of developing premature ESKD and
early death in the absence of specific cystine-depleting treat-
ment [1], whereas up to 5% present the milder late-onset form
[8]. Cysteamine treatment, which has been available since the
1980s, is able to preserve renal function and delay progression
to renal failure [21] and later reduce systemic involvement of
the disease [9, 10]. Oral cysteamine is able to achieve leucocyte
cystine depletion of up to 95% [22, 23] and reduce the cystine
parenchymal tissue content when adherence is consistent [21],
with substantial beneficial effects on renal and extra-renal co-
morbidities [4–7] and patient life expectancy [16, 17]. Data on
leucocyte cystine levels were not included in this study for
their concordance with patient self-report information on ad-
herence to be evaluated; however, the overall outcome of our
cohort of cystinotic patients concurs with data of other recent-
ly published series [6, 16, 17]. Indeed, at the time of the study,
40% of cystinotic patients in this series were adults, a finding
that reflects the impact of early diagnosis and cysteamine pre-
scription in most cases. Our results also indicate an improve-
ment in diagnosis and cysteamine initiation in this Spanish
cohort of patients who started the specific treatment with Cy-
stagon® during infancy and before 1 year of age in more than
half of the contemporary new cases, a fact that presumably will
be associated with better long-term outcome, as reported [5, 7,
11]. Our data also reflect the concept that cysteamine therapy
should be started as early as possible after diagnosis [6, 17, 21].
Prompt diagnosis and education of parents and children from
earlier ages on compliance would presumably also have a posi-
tive impact; hopefully, the children of today will be better ad-
herents when teenagers tomorrow.
Cysteamine is known not to be able to reverse the asso-
ciated Fanconi syndrome [3] or fully prevent progression to
chronic kidney disease (CKD) [16–18]. We found that, even
when treated, up to 47% of cystinotic patients progressed to
ESKD during childhood, receiving a KTx at ∼10 years of age
(8.75–13.75), an experience similar to that described by the
European ESPN-ERA registry [4]. In fact, almost 12 of 13
adult cystinotic patients in this series had been transplanted
during childhood and retransplantation was also very com-
mon, as reported elsewhere [4, 6, 7]. Although data on renal
function were not included in our survey, it seems reasonable
to presume that a large number of cystinotic children also suf-
fered CKD, as reported [10]. Therefore, most cystinotic pa-
tients would be transferred to adult KTx specialists who would
need to be aware not only of this rare disease [1] but also that
treatment will be lifelong, even after KTx [6, 17, 21].
This study confirms that patients understood the systemic
nature of nephropathic cystinosis, with early universal kidney
and eye involvement and progressive involvement of other
organs such as the intestine, cardiovascular system and CNS,
even after kidney transplantation [10] and mainly in low com-
pliant individuals [6, 7], which may be beyond the scope of the
F IGURE 2 : Self-reported adherence to cysteamine (Cystagon®) by
patient age.

























transplant specialist [18, 24]. In the present survey, the impact
of the disease on QOL was reported to be greater in adults than
in children, mainly affecting professional careers and social life;
this may be due to the onset of extra-renal complications over
time as expected [16–18] and cysteamine side effects, among
other factors [15]. Indeed, around one-third of our patients were
under the regular care of other physicians, mainly ophthalmolo-
gists and endocrinologists. In general, this kind of expertise may
exceed the skills of the regular adult nephrologist, who is often
focussed on transplantation. Therefore, the finding that only
44% of teenagers and adults with cystinosis in this study per-
ceived their doctors to be experts in the disease is not surprising,
in contrast to what occurs during childhood when the paediatric
nephrologist is considered the main reference as he/she usually
plays the role of patient care coordinator. As mentioned previ-
ously, systemic manifestations arising during adulthood warrant
specialized cystinosis-specific outpatient care, because manage-
ment usually requires expertise well beyond the skills of the indi-
vidual physician [17]; this again underlies the need for adequate
transfer of cystinotic patients to adult care [19].
Nevertheless, the major and most worrying finding of this
study is the alarming waning of adherence to cysteamine treat-
ment over time, predominantly in teenagers and adults [17].
In these patients, decreasing parental supervision, progressive
loss of dose reminder use and, more importantly, lack of
patient motivation coincide. It can be presumed, therefore,
that older cystinotic patients will face significant disease pro-
gression [6, 7], as reported in the past, when high rates of
extra-renal complications in adults with cystinosis [9] and lim-
itations of their life expectancy owing to poor compliance were
observed [17]. Despite the impact of treatment adherence on
prognosis, data regarding adherence to cysteamine are lacking.
Brief data presented as a poster recently reported missing
Cystagon® doses, a sustained and progressive decrease in
Cystagon®, refills with patient age and increasingly prolonged
gaps between refills over time [25]. This may also be influ-
enced by drug cost and availability, a factor not applicable in
Spain where Cystagon® is universally provided free of cost by
hospital pharmacies. Treatment with the new delayed-release
cysteamine formulation would presumably have a positive
impact on patient adherence [26, 27]. However, factors such as
disease complexity and limited awareness of the long-term
outcome of cystinosis may still determine patient compliance.
Nevertheless, suboptimal treatment adherence is not restricted
to cystinosis. Indeed, recent studies reported that 52–67% of
adult KTx recipients failed to follow their immunosuppressive
medications correctly, which increased the probability of graft
failure [28, 29]. These percentages were similar to those found in
our study and may indicate common CKD-related scenarios.
Moreover, measures targeting behavioural risk factors and active
patient involvement have been advocated to improve treatment
compliance in adult transplanted patients. Accordingly, similar
strategies should be implemented in young and adult cystinotic
patients [30].
It is to be hoped that new initiatives such as recently pub-
lished guidelines regarding awareness of cystinosis and its
impact on prognosis will lead to optimum, tailor-made care of
these patients [31].
This study was limited by a bias of patient response, paren-
tal opinion and lack of leucocyte cystine level monitoring to
ascertain actual compliance.
CONCLUSION
Despite severity of the disease and the impact of treatment on
outcome, adherence to Cystagon® wanes over time in cystino-
sis, particularly during adolescence and adulthood.
Our results underline the concept that early initiation of cy-
steamine treatment and the implementation of patient educa-
tion programmes stressing the benefits of good compliance are
essential for the long-term prognosis. In our Spanish cohort,
89% of patients under the age of 11 comply well with cystea-
mine, although this compliance tends to wane with age.
Because patients are awaiting new approaches to their treat-
ment, novel strategies such as patient self-care promotion,
better information on the disease, facilitated transition to adult
healthcare services guided by expert recommendations and
multidisciplinary teams are urgently required to improve the
clinical management of cystinosis.
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ABSTRACT
Background. MicroRNAs (miRs) are small non-coding RNAs
that are important regulators of gene expression and have
been implicated in atherosclerosis. Kidney injury distal to
atherosclerotic renal artery stenosis (ARAS) is aggravated by
atherosclerosis. Therefore, this study tested the hypothesis
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